Nanoparticles and the blood coagulation system. Part I: benefits of nanotechnology.

Nanotechnology is proven to provide certain benefits in drug delivery by improving solubility, increasing uptake to target sites and changing pharmacokinetics profiles of traditional drugs. Since properties of many materials change tremendously at the nanoscale levels, nanotechnology is also being explored in various industrial applications. As such, nanoparticles are rapidly entering various areas of industry, biology and medicine. The benefits of using nanotechnology for industrial and biomedical applications are often tempered by concerns about the safety of these new materials. One such area of concern includes their effect on the immune system. While nanoparticle interactions with various constituents of the immune system have been reviewed before, little attention was given to nanoparticle effects on the blood coagulation system. Nanoparticle interface with the blood coagulation system may lead to either benefits to the host or adverse reactions. This article reviews recent advances in our understanding of nanoparticle interactions with plasma coagulation factors, platelets, endothelial cells and leukocytes. Part I is focused on desirable interactions between nanoparticles and the coagulation system, and discusses benefits of using nanotechnology to intervene in coagulation disorders. Undesirable interactions posing safety concerns are covered in part II, which will be published in the June issue of Nanomedicine.

[1]  K. Leong,et al.  Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[2]  S. Unnikrishnan,et al.  The antithrombotic and antimicrobial properties of PEG-protected silver nanoparticle coated surfaces. , 2012, Biomaterials.

[3]  S A Wickline,et al.  Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. , 2007, Nanomedicine.

[4]  K. Jacobson,et al.  Functionalized congeners of P2Y1 receptor antagonists: 2-alkynyl (N)-methanocarba 2'-deoxyadenosine 3',5'-bisphosphate analogues and conjugation to a polyamidoamine (PAMAM) dendrimer carrier. , 2010, Bioconjugate chemistry.

[5]  T. VandenDriessche,et al.  Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment , 2007, Journal of thrombosis and haemostasis : JTH.

[6]  J. Spira,et al.  Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII – an open label, exploratory, cross‐over, phase I/II study , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  François Léonard,et al.  Electrical contacts to one- and two-dimensional nanomaterials. , 2011, Nature nanotechnology.

[8]  E. Chaikof,et al.  Reconstitution of CD39 in liposomes amplifies nucleoside triphosphate diphosphohydrolase activity and restores thromboregulatory properties. , 2006, Journal of vascular surgery.

[9]  P. Jurasz,et al.  Platelet–cancer interactions: mechanisms and pharmacology of tumour cell‐induced platelet aggregation , 2004, British journal of pharmacology.

[10]  P. Hoet,et al.  Interactions of nanomaterials with the immune system. , 2012, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[11]  S. Santra,et al.  Emerging nanotechnology-based strategies for the identification of microbial pathogenesis. , 2010, Advanced drug delivery reviews.

[12]  S. Kunapuli,et al.  P2Y12 receptor in platelet activation , 2011, Platelets.

[13]  Marina A Dobrovolskaia,et al.  Nanoparticles and the immune system. , 2010, Endocrinology.

[14]  G. Roosendaal,et al.  Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  D. Crommelin,et al.  Thrombolytic Treatment with Tissue-type Plasminogen Activator (t-PA) Containing Liposomes in Rabbits: a Comparison with Free t-PA , 1995, Thrombosis and Haemostasis.

[16]  P. Collins,et al.  Management of acquired haemophilia A , 2011, Journal of thrombosis and haemostasis : JTH.

[17]  Rebecca Robinson,et al.  Intravenous Hemostat: Nanotechnology to Halt Bleeding , 2009, Science Translational Medicine.

[18]  M. Penn,et al.  Affinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated platelets. , 2008, Biomaterials.

[19]  C. Napoli,et al.  Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases , 2009, Archives of pharmacal research.

[20]  W. Liles,et al.  Endothelial activation, dysfunction and permeability during severe infections , 2011, Current opinion in hematology.

[21]  R. Duncan,et al.  Nanomedicine(s) under the microscope. , 2011, Molecular pharmaceutics.

[22]  A. Weyrich,et al.  Platelet mRNA: the meaning behind the message , 2012, Current opinion in hematology.

[23]  Hidenori Suzuki,et al.  Novel platelet substitutes: disk-shaped biodegradable nanosheets and their enhanced effects on platelet aggregation. , 2009, Bioconjugate chemistry.

[24]  M. D. Alper,et al.  Detection of bacteria in suspension by using a superconducting quantum interference device , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. S. Dhadwar,et al.  Repeated oral administration of chitosan/DNA nanoparticles delivers functional FVIII with the absence of antibodies in hemophilia A mice , 2010, Journal of thrombosis and haemostasis : JTH.

[26]  B. Vaidya,et al.  Platelets directed liposomes for the delivery of streptokinase: development and characterization. , 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[27]  Maureane Hoffman,et al.  Remodeling the Blood Coagulation Cascade , 2003, Journal of Thrombosis and Thrombolysis.

[28]  H. Lee,et al.  Enhanced antimicrobial activity of nisin-loaded liposomal nanoparticles against foodborne pathogens. , 2012, Journal of food science.

[29]  T. Chung,et al.  Accelerating thrombolysis with chitosan-coated plasminogen activators encapsulated in poly-(lactide-co-glycolide) (PLGA) nanoparticles. , 2008, Biomaterials.

[30]  J. Grossiord,et al.  Low molecular weight heparin gels, based on nanoparticles, for topical delivery. , 2012, International journal of pharmaceutics.

[31]  B. Furie,et al.  Mechanisms of thrombus formation. , 2008, The New England journal of medicine.

[32]  F. Carinci,et al.  Assessment of Pain Associated with Insertion Torque of Dental Implants. A Prospective, Randomized-Controlled Study , 2011, International journal of immunopathology and pharmacology.

[33]  M. Dobrovolskaia,et al.  Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.

[34]  E. Ongini,et al.  A2A adenosine receptors in human peripheral blood cells , 2000, British journal of pharmacology.

[35]  D. Davalos,et al.  Fibrinogen as a key regulator of inflammation in disease , 2011, Seminars in Immunopathology.

[36]  Q. Jiang,et al.  Water-soluble Fe3O4 nanoparticles with high solubility for removal of heavy-metal ions from waste water. , 2012, Dalton transactions.

[37]  T. van der Poll,et al.  Disseminated intravascular coagulation in infectious disease. , 2010, Seminars in thrombosis and hemostasis.

[38]  B. Riske,et al.  Haemophilia Utilization Group Study – Part Va (HUGS Va): design, methods and baseline data , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[39]  T. Guo,et al.  EGFP-EGF1 protein-conjugated PEG-PLA nanoparticles for tissue factor targeted drug delivery. , 2010, Biomaterials.

[40]  J. Leach,et al.  Accelerated thrombolysis in a rabbit model of carotid artery thrombosis with liposome-encapsulated and microencapsulated streptokinase , 2003, Thrombosis and Haemostasis.

[41]  Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets. , 1987 .

[42]  Conglei Li,et al.  Crosstalk between Platelets and the Immune System: Old Systems with New Discoveries , 2012, Advances in hematology.

[43]  K. Lowe.  Second-Generation Perfluorocarbon Emulsion Blood Substitutes , 2000, Artificial cells, blood substitutes, and immobilization biotechnology.

[44]  Rekha Srinivasan,et al.  In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes. , 2009, Journal of biomedical materials research. Part A.

[45]  T. Whitsett,et al.  Accelerated thrombolysis and reperfusion in a canine model of myocardial infarction by liposomal encapsulation of streptokinase. , 1990, Circulation research.

[46]  N. J. Andrade,et al.  Antimicrobial effects of silver nanoparticles against bacterial cells adhered to stainless steel surfaces. , 2012, Journal of food protection.

[47]  A. Conte,et al.  Antimicrobial silver-montmorillonite nanoparticles to prolong the shelf life of fresh fruit salad. , 2011, International journal of food microbiology.

[48]  L. Thoma,et al.  A tumor vasculature targeted liposome delivery system for combretastatin A4: Design, characterization, and in vitro evaluation , 2006, AAPS PharmSciTech.

[49]  P. Avouris,et al.  Carbon-based electronics. , 2007, Nature nanotechnology.

[50]  Robert J Linhardt,et al.  Heparin-based nanoparticles. , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[51]  M. Baru,et al.  The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia , 2010, International journal of nanomedicine.

[52]  P. D. de Groot,et al.  Thrombin‐activatable fibrinolysis inhibitor is degraded by Salmonella enterica and Yersinia pestis , 2010, Journal of thrombosis and haemostasis : JTH.

[53]  Shaun P Jackson,et al.  The growing complexity of platelet aggregation. , 2007, Blood.

[54]  C. Esmon,et al.  Innate immunity and coagulation , 2011, Journal of Thrombosis and Haemostasis.

[55]  A. Wolberg,et al.  Procoagulant Activity in Hemostasis and Thrombosis: Virchow's Triad Revisited , 2012, Anesthesia and analgesia.

[56]  L. Goodnough,et al.  Recombinant factor VIIa: safety and efficacy , 2007, Current opinion in hematology.

[57]  Marina A Dobrovolskaia,et al.  Nanoparticles and the blood coagulation system. Part II: safety concerns. , 2013, Nanomedicine.

[58]  Barry S. Coller,et al.  Immobilized Arg-Gly-Asp (RGD) peptides of varying lengths as structural probes of the platelet glycoprotein IIb/IIIa receptor. , 1992 .

[59]  S. Gopinath,et al.  Anti-coagulant aptamers. , 2008, Thrombosis research.

[60]  C. Chen,et al.  A tissue factor targeted nanomedical system for thrombi-specific drug delivery. , 2012, Biomaterials.

[61]  K. Jacobson,et al.  Toward multivalent signaling across G protein-coupled receptors from poly(amidoamine) dendrimers. , 2008, Bioconjugate chemistry.

[62]  K. Nguyen,et al.  Biodegradable nanoparticles mimicking platelet binding as a targeted and controlled drug delivery system. , 2012, International journal of pharmaceutics.

[63]  Tanmay Bera,et al.  Characterization of antiplatelet properties of silver nanoparticles. , 2009, ACS nano.

[64]  Huan‐Tsung Chang,et al.  Highly efficient control of thrombin activity by multivalent nanoparticles. , 2011, Chemistry.

[65]  Kenichi A. Tanaka,et al.  Regulation of thrombin activity--pharmacologic and structural aspects. , 2007, Hematology/oncology clinics of North America.

[66]  J. Spira,et al.  Safety and efficacy of a long‐acting liposomal formulation of plasma‐derived factor VIII in haemophilia A patients , 2012, British journal of haematology.

[67]  A. Bredberg,et al.  Streptokinase antibodies inhibit reperfusion during thrombolytic therapy with streptokinase in acute myocardial infarction , 1999, Journal of internal medicine.

[68]  T. Bugge,et al.  Fibrin and fibrinolysis in infection and host defense , 2007, Journal of thrombosis and haemostasis : JTH.

[69]  A. Falanga,et al.  Overview of the Postulated Mechanisms Linking Cancer and Thrombosis , 2007, Pathophysiology of Haemostasis and Thrombosis.

[70]  R. Mariani-Costantini,et al.  Immunotoxicity of nanoparticles. , 2011, International journal of immunopathology and pharmacology.

[71]  S. D’Souza,et al.  Ligand Binding to GPIIb-IIIa: A Status Report , 1992, Seminars in thrombosis and hemostasis.

[72]  K. Jacobson,et al.  PEGylated dendritic unimolecular micelles as versatile carriers for ligands of G protein-coupled receptors. , 2009, Bioconjugate chemistry.

[73]  Kai Zacharowski,et al.  Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis? , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[74]  Huan‐Tsung Chang,et al.  Gold nanoparticles presenting hybridized self-assembled aptamers that exhibit enhanced inhibition of thrombin. , 2011, Angewandte Chemie.

[75]  P. Maincent,et al.  Preparation and In Vitro Evaluation of Heparin-Loaded Polymeric Nanoparticles , 2001, Drug delivery.

[76]  T. Bein,et al.  Heparin-coated colloidal mesoporous silica nanoparticles efficiently bind to antithrombin as an anticoagulant drug-delivery system. , 2012, Chemistry.

[77]  V. Torchilin,et al.  Liposomes for targeted delivery of antithrombotic drugs , 2008, Expert opinion on drug delivery.

[78]  T. Lecompte,et al.  In Vitro and In Vivo Evaluation of Oral Heparin–Loaded Polymeric Nanoparticles in Rabbits , 2002, Circulation.

[79]  A. Hollins,et al.  Antistreptokinase antibodies: implications for thrombolysis in a region with endemic streptococcal infection , 2005, Journal of Clinical Pathology.

[80]  Scott E McNeil,et al.  Translational considerations for cancer nanomedicine. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[81]  D. Vaughan,et al.  Streptokinase Entrapment in Interdigitation-Fusion Liposomes Improves Thrombolysis in an Experimental Rabbit Model , 1997, Thrombosis and Haemostasis.

[82]  T. Nishiya,et al.  Interaction of RGD liposomes with platelets. , 1996, Biochemical and biophysical research communications.

[83]  L. Thoma,et al.  A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies. , 2006, PDA journal of pharmaceutical science and technology.

[84]  Kathleen A. Johnson,et al.  Costs of care in hemophilia and possible implications of health care reform. , 2011, Hematology. American Society of Hematology. Education Program.

[85]  Miha Homar1,et al.  Toward Effective Long-Term Prevention of Thromboembolism: Novel Oral Anticoagulant Delivery Systems , 2010, Seminars in thrombosis and hemostasis.

[86]  Han‐Gon Choi,et al.  Prolonged systemic delivery of streptokinase using liposome , 1998, Archives of pharmacal research.

[87]  J. Leach,et al.  Distributed intraclot thrombolysis: mechanism of accelerated thrombolysis with encapsulated plasminogen activators , 2004, Journal of thrombosis and haemostasis : JTH.

[88]  S. Margel,et al.  Synthesis and characterization of recombinant factor VIIa-conjugated magnetic iron oxide nanoparticles for hemophilia treatment. , 2009, Journal of biomedical materials research. Part A.

[89]  R. Marchant,et al.  RGD-modified liposomes targeted to activated platelets as a potential vascular drug delivery system , 2004, Thrombosis and Haemostasis.

[90]  Paolo Prandoni,et al.  Cancer, thrombosis and heparin-induced thrombocytopenia. , 2007, Thrombosis research.